Estrogens, progesterone, and endometrial cancer

Area of Science:

• Reproductive Endocrinology
• Oncology
• Epidemiology

Background:

• Hormone replacement therapy (HRT) is commonly used for menopausal symptom management.
• Estrogen therapy, particularly unopposed estrogen, has been linked to an increased risk of endometrial cancer.
• The role of combined estrogen and progesterone therapy in endometrial cancer risk requires further clarification.

Purpose of the Study:

• To investigate the association between estrogen-only and combined estrogen-progesterone replacement therapy and the risk of endometrial cancer.
• To quantify the risk of endometrial cancer associated with different durations of unopposed estrogen use.
• To evaluate the protective effect of medroxyprogesterone acetate when used in combination with estrogen therapy.

Main Methods:

• A case-control study was conducted among women aged 50-64 years.
• 172 incident cases of endometrial cancer were identified between 1979 and 1989.
• Controls were matched for age and duration of health plan membership.

Main Results:

• Women using conjugated estrogens alone for 5 or more years had a significantly increased risk of endometrial cancer (adjusted RR = 22.0).
• Users of unopposed estrogens for 3-4 years showed a relative risk of 1.9.
• Combination therapy with medroxyprogesterone acetate for 3 or more years resulted in a risk similar to nonusers (adjusted RR = 1.3).

Conclusions:

• Long-term use of unopposed estrogen therapy is a substantial risk factor for endometrial cancer.
• The addition of medroxyprogesterone acetate to estrogen therapy appears to neutralize the increased endometrial cancer risk.
• Combined hormone replacement therapy may offer a safer option for women requiring menopausal symptom management.